[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"respiratory-tract-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:respiratory-tract-diseases":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,49,86,116,142,175,205,237,264],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":4,"leadSponsor":45,"locationsCount":48},"100093036","collection-of-lung-fluid-and-tissue-samples-for-research-100093036",false,"NCT00471250","Collection of Lung Fluid and Tissue Samples for Research","Research Respiratory Tract Procedures","* HEALTHY VOLUNTEER INCLUSION CRITERIA FOR BRONCHOSCOPY AND BRONCHOSCOPIC PROCEDURES:\n\n  1. 18 to 75 years of age inclusive\n  2. Enrolled without regard to gender, race, or ethnicity\n  3. NIH staff are eligible\n  4. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process\n  5. Able and willing to complete the informed consent process\n  6. Able and willing to arrange to have another person drive them home after the procedure\n  7. Able and willing not to eat or drink anything for 6 hours prior and 2 hours after the procedure\n  8. Willing to donate blood and respiratory tract samples for storage to be used for future research\n  9. In good general health without clinically significant medical history\n  10. Physical examination without clinically significant findings\n  11. Screening laboratory tests without clinically significant abnormalities:\n* Complete blood count with differential\n* Serum chemistries including creatinine, blood urea nitrogen, glucose, liver enzymes and function tests, electrolytes\n* HIV test and hepatitis serologies (HBsAg; HCV) if status is unknown\n* Prothrombin time, partial thromboplastin time\n* Urinalysis\n* Female subjects must have negative urine pregnancy test within 1 week of participation and continue birth control practices prior to participation\n* Chest radiograph (CXR) (if the subject has not had a CXR or computerized tomography \\[CT\\] scan of the chest within the prior 7 days)\n* Pulse oximetry\n* Electrocardiogram (ECG)\n* Treadmill exercise stress test (as indicated for history of angina or abnormalities on ECG)\n\nHEALTHY VOLUNTEER EXCLUSION CRITERIA FOR BRONCHOSCOPY AND BRONCHOSCOPIC PROCEDURES:\n\n1. \\\u003C18 or \\>75 years old\n2. A smoking history of 10 pack-years or more, a current smoker, or tobacco free for less than a year.\n3. Positive HIV status. Subjects must have a negative FDA-approved HIV blood test. \\[Note: Results of HIV enzyme-linked immunosorbent assay (ELISA) will be documented, but a negative HIV polymerase chain reaction (PCR) test result will be sufficient for eligibility screening of subjects with positive HIV ELISA that is due to prior participation in an HIV vaccine study\\]\n4. Acute or chronic hepatitis based on viral hepatitis serologies\n5. Pregnancy or breastfeeding\n6. Any active medical problems especially bleeding disorders, significant bruising or bleeding difficulties with intramuscular (IM) injections or blood draws, use of anticoagulants, or pulmonary disorders including asthma\n7. History of allergic reaction to lidocaine, sedative medications like Valium Trademark or Versed Trademark, or narcotic medications like morphine or fentanyl\n8. Immunosuppressive medications, cytotoxic medications, inhaled corticosteroids, or long-acting beta-agonists within the past three months. (Note that use of corticosteroid nasal spray for allergic rhinitis, topical corticosteroids for an acute uncomplicated dermatitis, or short-acting beta-agonists in controlled asthmatics is not excluded).\n9. Use of platelet inhibitors including aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) within 7 days of procedure\n10. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer s ability to give informed consent\n\nPATIENT INCLUSION CRITERIA FOR BRONCHOSCOPY AND BRONCHOSCOPIC PROCEDURES\n\n1. 18 to 75 years of age inclusive\n2. Known or suspected respiratory infections or infection susceptibility\n3. Enrolled without regard to gender, race, or ethnicity\n4. Must be enrolled in a concurrent NIH protocol and under the care of a primary physician outside of the NIH\n5. Able and willing to complete informed consent process\n6. Able and willing to arrange to have another person drive them home after the procedure\n7. Able and willing not to eat or drink anything for 6 hours prior and 2 hours after the procedure\n8. Willing to donate blood and respiratory tract samples for storage to be used for future research\n\nPATIENT EXCLUSION CRITERIA FOR BRONCHOSCOPY AND BRONCHOSCOPIC PROCEDURES\n\n1. \\\u003C18 or \\>75 years old\n2. History of recent\u002Facute clinically significant pulmonary compromise. This will be defined by the following criteria:\n\n   * New lung infection or change in status of chronic lung infection or significant new findings on chest x-ray or CT scan\n   * Asthma that is unstable or required emergent care, urgent care, hospitalization, or intubation during the past two years, or that required the use of oral or parenteral corticosteroids during the past two years\n   * Clinically significant reactive airway disease that does not respond to bronchodilators\n   * Unstable chronic lung disease such as Chronic Obstructive Pulmonary Disease (COPD) or pulmonary fibrosis\n   * History of pulmonary hypertension\n   * Requirement of supplemental oxygen at rest\n3. Unstable angina or uncontrolled heart failure or rhythm disturbance\n4. Significant kidney or liver disease\n5. Significant anemia with a hemoglobin of less than 7.5 grams\u002Fdl.\n6. Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions), significant bruising or bleeding difficulties with IM injections or blood draws, or use of anticoagulant medications\n7. Use of platelet inhibitors including aspirin and NSAIDs within 7 days of procedure or clopidogrel (Plavix Trademark) within 14 days of procedure or the inability to safely stop platelet inhibitors for 7-14 days prior to procedures\n8. History of allergic reaction to lidocaine, sedative medications like Valium Trademark or Versed Trademark, or narcotic medications like morphine or fentanyl\n9. Pregnancy or breastfeeding\n10. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent\n\nHEALTHY VOLUNTEER INCLUSION CRITERIA FOR NASAL MUCOSAL BIOPSY, NASAL NITRIC OXIDE MEASUREMENT, AND NASAL POTENTIAL DIFFERENCE MEASUREMENT:\n\n1. \\>= 5 years old\n2. Enrolled without regard to gender, race, or ethnicity\n3. NIH staff are eligible\n4. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process\n5. Able and willing to complete the informed consent process\n6. Willing to donate blood and respiratory tract samples for storage to be used for future research\n7. Stable vital signs\n\nHEALTHY VOLUNTEER EXCLUSION CRITERIA FOR NASAL MUCOSAL BIOPSY, NASAL NITRIC OXIDE MEASUREMENT, AND NASAL POTENTIAL DIFFERENCE MEASUREMENT:\n\n1. \\\u003C5 years old\n2. History of frequent colds or significant uncontrolled hay fever symptoms, recent or active upper respiratory tract infection, such as a cold or sinusitis, or chronic sinus infection or congestion\n3. History of turbinectomy or significant nasal pathology that would preclude obtaining mucosal scrape biopsies or other measures\n4. Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions), significant bruising or bleeding difficulties with IM injections or blood draws, or use of anticoagulant medications\n5. The use of nasal steroids in the past 6 weeks\n6. Any medical, psychiatric, social condition, occupational reason, or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer s ability to give informed consent\n\nPATIENT INCLUSION CRITERIA FOR NASAL MUCOSAL BIOPSY, NASAL NITRIC OXIDE MEASUREMENT, NASAL POTENTIAL DIFFERENCE MEASUREMENT, SPUTUM INDUCTION, COUGH AEROSOL SAMPLING, EXHALED AEROSOL MASK SAMPLE COLLECTION, COLLECTION OF EXHALED PARTICLES, AND LCI:\n\n1. \\>= 5 years old\n2. Known or suspected infections or infection susceptibility\n3. Enrolled without regard to gender, race, or ethnicity\n4. Must be enrolled in a concurrent NIH protocol and under the care of a primary physician outside of the NIH\n5. Able and willing to complete informed consent process\n6. Willing to donate blood and respiratory tract samples for storage to be used for future research\n\nPATIENT EXCLUSION CRITERIA FOR NASAL MUCOSAL BIOPSY, NASAL NITRIC OXIDE MEASUREMENT, NASAL POTENTIAL DIFFERENCE MEASUREMENT, SPUTUM INDUCTION, COUGH AEROSOL SAMPLING, EXHALED AEROSOL MASK SAMPLE COLLECTION, COLLECTION OF EXHALED PARTICLES, AND LCI:\n\n1. \\\u003C5 years old\n2. Significant uncontrolled hay fever symptoms or recent or active upper respiratory tract infection, such as a cold or sinusitis\n3. History of turbinectomy or significant nasal pathology that would preclude obtaining mucosal scrape biopsies or other measures\n4. Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions), significant bruising or bleeding difficulties with IM injections or blood draws, or use of anticoagulant medications\n5. Any medical, psychiatric, social condition, occupational reason, or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent.\n\nHEALTHY VOLUNTEER INCLUSION CRITERIA FOR SPUTUM INDUCTION, EXHALED BREATH CONDENSATE COLLECTION COUGH AEROSOL SAMPLING, EXHALED AEROSOL MASK SAMPLE COLLECTION, COLLECTION OF EXHALED PARTICLES, AND LCI:\n\n1. \\>= 5 years old\n2. Enrolled without regard to gender, race, or ethnicity\n3. NIH employees or non-employees eligible\n4. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process\n5. Able and willing to complete the informed consent process\n6. Willing to donate blood and respiratory tract samples for storage to be used for future research\n7. Stable vital signs\n\nHEALTHY VOLUNTEER EXCLUSION CRITERIA FOR SPUTUM INDUCTION, EXHALED BREATH CONDENSATE COLLECTION, COUGH AEROSOL SAMPLING, EXHALED AEROSOL MASK SAMPLE COLLECTION, COLLECTION OF EXHALED PARTICLES, AND LCI:\n\n1. \\\u003C 5 years old\n2. History of asthma or reactive airways disease\n3. Any medical, psychiatric, social condition, occupational reason, or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer s ability to give informed consent\n\nPATIENT INCLUSION CRITERIA FOR SPUTUM INDUCTION, EXHALED BREATH CONDENSATE COLLECTION, COUGH AEROSOL SAMPLING, EXHALED AEROSOL MASK SAMPLE COLLECTION, COLLECTION OF EXHALED PARTICLES, AND LCI:\n\n1. \\>= 5 years old\n2. Known or suspected infections or infection susceptibility\n3. Enrolled without regard to gender, race, or ethnicity\n4. Must be enrolled in a concurrent NIH protocol and under the care of a primary physician outside of the NIH\n5. Able and willing to complete informed consent process\n6. Willing to donate blood and respiratory tract samples for storage to be used for future research\n\nPATIENT EXCLUSION CRITERIA FOR SPUTUM INDUCTION, EXHALED BREATH CONDENSATE, COUGH AEROSOL SAMPLING, EXHALED AEROSOL MASK SAMPLE COLLECTION, COLLECTION OF EXHALED PARTICLES, AND LCI:\n\n1. \\\u003C 5 years old\n2. Significant uncontrolled asthma or reactive airways disease\n3. Any medical, psychiatric, social condition, occupational reason, or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer s ability to give informed consent.",true,"ALL","5 Years","100 Years",{"count":21,"type":22},550,"ESTIMATED","OBSERVATIONAL","This study will collect fluid and tissue specimens from the lungs and nose of healthy people and people with a history of lung infections. The specimens will be examined for differences between the two groups that may be associated with susceptibility to certain infections.\n\nHealthy normal volunteers and people with a history of lung infections between 18 and 75 years of age who are followed at NIH may be eligible for this study.\n\nParticipants undergo the following procedures:\n\nMedical history and physical examination.\n\nBlood and urine tests.\n\nElectrocardiogram (ECG) and chest x-ray.\n\nTreadmill exercise stress test (for people over 45 years old with a history of chest pain or ECG abnormalities).\n\nBronchoscopy: The subject s nose and throat are numbed with lidocaine and a sedative is given for comfort. A thin flexible tube called a bronchoscope is advanced through the nose or mouth into the lung airways to examine the airways carefully.\n\nFluid collection during the bronchoscopy using one of the following methods:\n\n* Bronchoalveolar lavage: Salt water is injected through the bronchoscope into the lung and immediately suctioned out, washing off cells lining the airways.\n* Bronchial brushings: A brush-tipped wire enclosed in a sheath is passed through the bronchoscope and a small area of the airway tissue is gently brushed. The brush is withdrawn with some tissue adhering to it.\n* Endobronchial biopsies: Small pinchers on a wire are passed through the bronchoscope and about 1 to 2 millimeters of tissue is removed.\n* Nasal scrape: A small device is used to scrape along the inside of the nose to collect some cells.\n* Sputum induction\n* Exhaled breath condensate to obtain specimens for in vitro investigations and comparisons of both the cellular and acellular components.\n* Nasal nitric oxide production\n* Nasal potential difference\n* Exhaled aerosol mask sample collection\n* Cough aerosol collection\n* Exhaled particle collection\n* Lung Clearance Index (LCI)",[26,27,28],"Leukocyte Disorders","Respiratory Tract Diseases","Bronchoscopy",[30,31,32,33,34,35,36,37],"Lung Infection Susceptibility","Bronchoalvealar lavage","Nasal Biopsy","Sputum Sample","Infection Susceptibility","Natural History","Healthy Volunteer","HV","RECRUITING","2026-05-29",{"date":41,"type":42},"2026-06-01","ACTUAL",{"date":44,"type":42},"2007-08-17",{"name":46,"class":47},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":73,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":85},"100382700","phase-4-clinical-surveillance-vs-anticoagulation-for-low-risk-patients-with-isolated-subsegmental-pulmonary-embolism-100382700","NCT04263038","Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism","Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism: a Multicenter Randomized Placebo-controlled Non-inferiority Trial","SAFE-SSPE","Inclusion Criteria:\n\n1. Informed Consent as documented by signature\n2. Age ≥18 years\n3. Objective diagnosis of symptomatic or asymptomatic isolated SSPE\n\nExclusion Criteria:\n\n1. Presence of leg deep vein thrombosis (DVT) or upper extremity DVT (subclavian vein or above)\n2. Active cancer, defined as cancer treated with surgery, chemotherapy, radiotherapy, or palliative care during the last 6 months\n3. ≥1 prior episode of unprovoked VTE (absence of a transient or permanent risk factor)\n4. Clinical instability (systolic blood pressure \\\u003C100 mm Hg or arterial Oxygen saturation \\\u003C92% at ambient air) at the time of presentation\n5. Active bleeding or at high risk of bleeding\n6. Severe renal failure (creatinine clearance \\\u003C30ml\u002Fmin)\n7. Severe liver insufficiency (Child-Pugh B or C)\n8. Concomitant use of strong CYP3A4 inhibitors or strong CYP3A4 inducers\n9. Known hypersensitivity to rivaroxaban\n10. Need for therapeutic anticoagulation for another reason\n11. Therapeutic anticoagulation for \\>72 hours for any reason at the time of screening\n12. Hospitalized for \\>72 hours prior to the diagnosis of isolated SSP (hospital-acquired VTE)\n13. Known pregnancy or breast feeding (pregnancy test to be performed for women of childbearing potential)\n14. Lack of safe contraception in women of childbearing potential\n15. Refusal or inability to provide informed consent\n16. Prior enrolment in this trial","18 Years",{"count":59,"type":22},276,"INTERVENTIONAL",[62],"PHASE4","The clinical significance of pulmonary embolism (PE) limited to the subsegmental pulmonary arteries, so called isolated subsegmental pulmonary embolism (SSPE), remains controversial. Whether isolated SSPE represents \"true\" PE, a clinically more benign form of PE, a physiologic lung clearing process, or a false positive result (artifact) is currently unclear and hence, whether patients with isolated SSPE benefit from anticoagulant treatment is uncertain. Despite growing evidence from observational studies that withholding anticoagulation may be a safe option in selected patients with isolated SSPE (i.e., those without concomitant deep vein thrombosis, cancer, etc.), most patients with isolated SSPE receive anticoagulant treatment, which is associated with an increased risk of bleeding. The overall objective of the randomized controlled SAFE-SSPE trial is to evaluate the efficacy and safety of clinical surveillance without anticoagulation compared to anticoagulation treatment in low-risk patients with isolated SSPE.",[65,66,67,68,69,27,70,71,72],"Pulmonary Embolism","Embolism","Embolism and Thrombosis","Lung Diseases","Cardiovascular Diseases","Venous Thromboembolism","Anticoagulant-induced Bleeding","Bleeding",[74],"subsegmental pulmonary embolism","2026-05-20",{"date":77,"type":42},"2026-05-22",{"date":79,"type":42},"2020-05-15",{"date":81,"type":22},"2028-05",{"name":83,"class":84},"Drahomir Aujesky","OTHER",40,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":93,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":96,"conditions":97,"keywords":103,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":48},"100569263","aevicemd-for-detection-of-wheeze-in-pediatric-and-adult-populations-100569263","NCT06691971","AeviceMD for Detection of Wheeze in Pediatric and Adult Populations","A Pilot Study to Assess Aevice Medical Device for Detection of Wheeze in Pediatric and Adult Populations","Inclusion Criteria:\n\n* The subject is willing and\u002For parents\u002Fguardians are able to give informed consent for participation in the study.\n* Male or Female, aged ≥ 3 years.\n* Diagnosed with acute asthma exacerbation by an ED provider.\n\nExclusion Criteria:\n\n* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the subjects at risk because of participation in the study, or may influence the result of the study, or the subject's ability to participate in the study.","3 Years",{"count":95,"type":22},160,"Respiratory signs and symptoms consisting of wheeze, cough, and breathlessness are obtained in a manual fashion through history taking and physical examination by the healthcare professional. Auscultation of the lung assesses airflow through the trachea-bronchial tree and is helpful in diagnosing various respiratory disorders. AeviceMD is a wearable device that can acquire and process lung sounds, thus assisting in the detection of abnormal lung sounds. The primary objective of this study is to determine if AeviceMD can detect wheeze of pediatrics and adults as accurately as a physician through auscultation. The secondary objective is to investigate if AeviceMD can be used for remote auscultation of breath sounds.",[98,99,100,27,101,102],"Subject Presenting Wheeze","Asthma","Bronchial Disease","Pediatric Asthma","Chronic Respiratory Disease",[104,105,106],"Wheeze","Auscultation","Wearable Medical Device","2025-09-30",{"date":109,"type":42},"2025-10-03",{"date":111,"type":42},"2023-06-29",{"date":113,"type":22},"2026-12",{"name":115,"class":84},"Aevice Health Pte. Ltd.",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":16,"sex":17,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":126,"studyType":23,"phases":4,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":4},"100608081","prospective-cohort-of-integrated-traditional-chinese-and-western-medicine-in-china-100608081","NCT07196917","Prospective Cohort of Integrated Traditional Chinese and Western Medicine in China","Inclusion Criteria:\n\nAge: Participants aged 30 to 74 years\n\nPhysical Functionality: Free from severe physical disabilities impacting mobility or communication, with preserved ability to comprehend and respond to study procedures\n\nInformed Consent: Capable of providing written informed consent voluntarily after receiving full study disclosure\n\nExclusion Criteria:\n\nResidents living in functional areas (e.g., work sheds, military units, student dormitories, nursing homes, etc.)\n\nIndividuals unable to communicate normally","30 Years","74 Years",{"count":125,"type":22},1000000,"10 Years","To further explore the application prospects of integrated Traditional Chinese and Western medicine in chronic disease prevention and control and health management, this study intends to establish a large, prospective, integrated Traditional Chinese and Western medicine cohort in Hubei Province. This study will conduct long-term follow-up and multi-dimensional data collection to systematically reveal the associations between Traditional Chinese Medicine (TCM) constitution types and chronic diseases, the aging process, and multi-morbidity, thereby developing an integrated health management strategy with local characteristics. This study will fill the current gap in systematic evidence linking TCM constitutions to the prevalence of modern diseases, providing a solid demographic and biological foundation for the integrated development of Traditional Chinese and Western medicine. It will also contribute to meeting the needs for early disease warning, early intervention, and personalized care under the \"Healthy China\" strategic goal.",[69,27,129,130,131],"Cancer","Endocrine System Diseases","Death","NOT_YET_RECRUITING","2025-09-29",{"date":135,"type":42},"2025-10-02",{"date":137,"type":22},"2025-10-01",{"date":139,"type":22},"2027-12-31",{"name":141,"class":84},"Huazhong University of Science and Technology",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":16,"sex":17,"minAge":149,"maxAge":123,"enrollmentInfo":150,"targetDuration":4,"studyType":60,"phases":152,"briefSummary":154,"conditions":155,"keywords":161,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":48},"100592093","early-intervention-strategies-for-lung-cancer-100592093","NCT06988943","Early Intervention Strategies for Lung Cancer","Construction and Evaluation of a Hospital-Community Health Collaboration Model Empowered by Digital Technology for Lung Cancer Screening","1.Community Health Service Centers (Cluster Level)\n\n1. Inclusion Criteria The community health service center must be located within one of the 11 districts of Guangzhou.\n\n   The center must manage a population of over 10,000 elderly individuals. The center should be equipped with at least one CT machine and have qualified medical personnel, such as radiologists, radiologic technicians, and nursing staff.\n2. Exclusion Criteria Community health centers currently participating in other public health projects or studies that may affect screening results.\n\nCommunity health service centers where researchers cannot collect data or conduct follow-up.\n\n2\\. Screening Subjects (Individual Level)\n\n1. Inclusion Criteria Aged 40-75 years. Residing in the community participating in the study for a long time. No known history of lung cancer and has not undergone lung cancer screening in the past three months.\n\n   Able to understand and willing to sign the informed consent form, and able to participate in long-term follow-up.\n2. Exclusion Criteria Individuals diagnosed with lung cancer. Individuals with severe other health issues that make them unsuitable for CT imaging.\n\nIndividuals unable to understand the study protocol or who cannot provide informed consent due to cognitive impairments.\n\nIndividuals participating in other clinical trials that may affect the results of this study.\n\nIndividuals unable to undergo follow-up.","40 Years",{"count":151,"type":22},16000,[153],"NA","Low-dose CT (LDCT）can detect and treat lung cancer earlier and more quickly, while expanded screening coverage helps reduce the incidence and mortality of respiratory diseases such as lung cancer. This study aims to conduct a single-arm cluster randomized trial of digitally enabled LDCT in Guangzhou to assess its intervention effectiveness and cost-effectiveness.",[156,157,158,159,68,27,160],"Respiratory Tract Neoplasms","Thoracic Neoplasms","Neoplasms by Site","Neoplasms","Lung Neoplasms",[162,163,164,165],"Screning test","Lung cancer","LDCT","Low-dose CT","2025-05-26",{"date":168,"type":42},"2025-05-30",{"date":170,"type":42},"2024-06-25",{"date":172,"type":22},"2025-06",{"name":174,"class":84},"The First Affiliated Hospital of Guangzhou Medical University",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":182,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":60,"phases":186,"briefSummary":187,"conditions":188,"keywords":190,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":4},"100584736","the-effect-of-virtual-reality-goggles-and-distraction-cards-applied-to-children-aged-6-12-years-during-inhaler-therapy-on-physiological-parameters-and-anxiety-100584736","NCT06893237","The Effect of Virtual Reality Goggles and Distraction Cards Applied to Children Aged 6-12 Years During Inhaler Therapy on Physiological Parameters and Anxiety","The Effect of Virtual Reality Goggles and Distraction Cards Applied to Children Aged 6-12 Years During Inhaler Therapy on Physiological Parameters and Anxiety: a Randomised Controlled Study","Inclusion Criteria:\n\n* The child is receiving inhalation (salbutamol) treatment in the pediatric intensive care unit.\n* The child must be between 6-12 years old\n* The child must not have any vision or hearing problems.\n* Being conscious and being able to communicate verbally\n* After being informed, the child and parent agree to participate in the study in writing and verbally\n* No genetic, congenital, chronic or metabolic disease\n* The child has no signs of respiratory failure\n\nExclusion Criteria:\n\n* The child's clinical treatment is due to a history of surgery,\n* The child is taking a sedative medication,\n* The child has a fever over 37°C,\n* The child has applied with a severe asthma attack,\n* The child's saturation value is below 92% at the time of application.","6 Years","12 Years",{"count":185,"type":22},108,[153],"In the literature, studies examining the effect of virtual reality application on physiological parameters and anxiety during inhalation therapy, which is frequently used in children, are quite limited. Therefore, this study will be conducted to determine the effect of virtual reality goggles and distraction cards on physiological parameters and anxiety in patients receiving inhalation therapy.",[189,27],"Respiratory Infections, Acute",[191,192,193,194,195],"inhalation therapy","child","virtual reality glasses","anxiety","distraction of attention","2025-03-25",{"date":198,"type":42},"2025-03-30",{"date":200,"type":22},"2025-04",{"date":202,"type":22},"2026-04",{"name":204,"class":84},"Uskudar University",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":60,"phases":215,"briefSummary":217,"conditions":218,"keywords":223,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":4},"100539829","phase-2-mrg-001-as-an-immunoregulatory-and-regenerative-therapy-for-ards-patients-100539829","NCT06308926","MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients","A Phase IIa, Double-Blind, Randomized, Multi-Center Study Comparing MRG-001 to Placebo in Patients With Acute Respiratory Distress Syndrome","SUMMIT","Inclusion Criteria:\n\nAcute Respiratory Distress Syndrome, manifested by the following and not explained by alternative diagnoses, for example but not limited to: Pulmonary Edema due to Congestive Heart Failure (CHF).\n\n1. Chest x-ray (CXR)\\* revealing bilateral infiltrates involving a minimum of three quadrants on frontal chest radiograph, consistent with pulmonary edema or bilateral ground glass opacities not fully explained by effusions, lobar or lung collapse, nodules, atelectasis or other etiology of infiltrates not due to ARDS.\n2. PaO2\u002FFiO2 \\\u003C 300.\n3. Requiring respiratory support \\[defined as mechanical ventilation, non-invasive ventilation (NIV) or high flow nasal canula (HFNC)\\] If on ventilator, settings must include positive end-expiratory pressure (PEEP) or continuous positive airway pressure (CPAP) ≥5 cm H2O.\n\nExclusion Criteria:\n\n1. Age less than 18 years.\n2. Infiltrates with etiology suspected of mimicking ARDS, ie; Pulmonary Edema due to Congestive Heart Failure (CHF). (A Pulmonary Arterial Wedge Pressure (PAWP) of \\\u003C 18 for \\>12 hours would rule out suspected CHF).\n3. Pregnancy documented or suspected in women of child bearing potential, unless ruled out by a negative pregnancy test during screening or breast feeding.\n4. Immunocompromised patients:\n\n   4.1. Organ or bone marrow transplant recipients and\u002For recent (within 2 months) chronic use of immunosuppressive drugs (tacrolimus, mycofenolate mofetil, cyclosporine, rapamycine, hydrochloroquine, azathiopurine, methotrexate), e.g., biologicals, JAK1\u002F2 inhibitors, interferons, interleukins, (prednisone or related corticosteroids are allowed).\n\n   4.2. Patients with documented or suspected HIV\u002FAIDS, hepatitis B\u002FC or active lung disease with tuberculosis. 4.3. Patients with active cancer diagnosis or use of chemotherapy in the past 3 months.\n5. Hypersensitivity to either of the components of MRG-001.\n6. The patient is known or suspected to be brain dead or is moribund (not expected to live \\>48 hours) or is unlikely to survive long enough to receive 3 injections (4 days) in the opinion of the investigator.\n7. The primary care physician is not committed to full support of the patient. (A DNR representing \"no chest compression\" only, would not necessarily be an exclusion. A DNR in which life support is withheld\u002Fwithdrawn or is otherwise limited, would be an exclusion).\n8. Participation in another investigational protocol or use of another investigational drug within 30 days of enrollment.\n9. Enrollment time window has been exceeded (must be enrolled within 7 days of hospital admission and within 48 hours of development of ARDS).\n10. Significant pre-existing organ dysfunction prior to randomization:\n\n    10.1. Lung: Receiving supplemental home oxygen therapy at baseline for pre-existing medical condition (other than COVID-19), as documented in medical record. 10.2. Heart: Pre-existing congestive heart failure defined as an ejection fraction \\\u003C20% as documented in the medical record. Clinically significant ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation), unstable angina, myocardial infarction (past 3 months), heart and coronary vessel surgery (past 3 months), significant valvular heart disease, uncontrolled arterial hypertension with systolic blood pressure \\>180 mm Hg and diastolic blood pressure \\>110 mm Hg. WHO Class III or IV pulmonary hypertension. 10.3. Renal: End-stage renal disease requiring renal replacement therapy or eGFR \\\u003C30 mL\u002Fmin. 10.4. Liver: Severe chronic liver disease defined as Child-Pugh Class C or pre-existing severe hepatic dysfunction (i.e.; portal hypertension, cirrhosis, ascites, esophageal variceal bleeding, acute hepatic necrosis). 10.5. Hematologic: Baseline platelet count \\\u003C30,000\u002Fmm3 or hemoglobin levels \\\u003C6.0 g\u002FdL. 10.6. Neurological: Severe traumatic brain injury, with intracranial injury demonstrated by head CT 10.7. History of splenectomy or splenomegaly (spleen weighing \\> 750 g).\n11. Currently receiving extracorporeal life support (ECLS\u002FECMO) or high-frequency oscillatory ventilation (HFOV).\n12. Anticipated extubation within 24 hours of enrollment.",{"count":214,"type":22},60,[216],"PHASE2","This is a phase IIa, dose-ranging, proof-of-concept study of MRG-001 in patients with ARDS.\n\nThe aim is to determine the safety and preliminary efficacy of MRG-001 across two dose ranges.",[219,220,221,27,222],"Acute Respiratory Distress Syndrome","Respiratory Failure","Respiratory Distress Syndrome","Cytokine Storm",[219,224,225,226],"MRG-001","Stem Cells","Immunomodulation","2024-08-22",{"date":229,"type":42},"2024-08-23",{"date":231,"type":22},"2024-12-01",{"date":233,"type":22},"2026-07-01",{"name":235,"class":236},"MedRegen LLC","INDUSTRY",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":245,"conditions":246,"keywords":251,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":48},"100536562","m-avium-wgs-during-mav-pd-treatment-100536562","NCT06266442","M. Avium WGS During Mav-PD Treatment","Longitudinal Assessment of Clinical Pulmonary Mycobacterium Avium Isolates in Treated Patients Using Whole Genome Sequencing","Inclusion Criteria:\n\n* Age 18 and older\n* Willing to provide informed consent and participate in study procedures\n* Residing continuously in Ontario during the past five years\n* Mav-PD, either initial or recurrent (previously treated patients will be eligible) five years\n* Meet American Thoracic Society (ATS) \u002F Infectious Diseases Society of America (IDSA) NTM disease criteria for Mav-PD\n\nExclusion Criteria:\n\n* Lack of an available pre-treatment M. avium isolate in the PHOL isolate bank\n* The inability to produce sputum either spontaneously or by induction with nebulized hypertonic saline\n* Cavitation \\>3 cm internal diameter\n* Known macrolide-resistant MAC infection\n* HIV infection\n* Known diagnosis of cystic fibrosis\n* History of solid organ or hematological transplantation\n* Severe comorbid illness that is reasonably expected to limit survival to \\\u003C24 months\n* Residing in mid\u002Fnorth York region (King, Aurora, Newmarket, Whitechurch-Stouffville, East Gwillimbury or Georgina)\n* Having moved between regions (Toronto\u002Fsouthern York region vs non-Toronto\u002FYork region vs mid-northern York region) within the past 5 years",{"count":85,"type":22},"This is a prospective observational study using whole genome sequencing (WGS) to investigate whether new strains (other than the initially identified strain(s)) of M. avium are responsible for persistently culture positive sputum during treatment (refractory disease), or the reversion to culture positive sputum after prior conversion to negative. The study will further investigate for differences between participants living in the Toronto\u002FYork region versus participants living elsewhere.\n\nThe primary goal of this prospective observational study is to understand why some patients with M. avium lung disease have persistent or recurrent M. avium in their sputum despite treatment. The aim is to understand whether it is usually due to treatment failure or new infection.",[247,248,249,250,27],"Mycobacterium Avium","Mycobacterium Infections, Nontuberculous","Mycobacterium Infections","Nontuberculous Mycobacterial Lung Disease",[252,253,254],"Nontuberculous mycobacterium","Whole genome sequencing","Mycobacterium avium","2024-05-17",{"date":257,"type":42},"2024-05-21",{"date":259,"type":42},"2024-05-13",{"date":261,"type":22},"2026-09",{"name":263,"class":84},"University Health Network, Toronto",{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":271,"enrollmentInfo":272,"targetDuration":4,"studyType":60,"phases":274,"briefSummary":275,"conditions":276,"keywords":280,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":48},"100529757","phase-2-a-phase--clinical-study-of-adebrelimab-combined-with-chemotherapy-and-concurrent-radiotherapy-for-extensive-stage-oligometastatic-sclc-100529757","NCT06177925","A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC","A Phase Ⅱ Exploratory Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy as First-Line Treatment for Extensive-Stage Oligometastatic Small Cell Lung Cancer","Inclusion Criteria:\n\n* Signed inform consent form\n* Age \\>= 18 years and \\\u003C= 75 years\n* Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration Lung Study Group \\[VALG\\] staging system)，the number of metastatic lesions ≤ 5, the number of metastatic organs ≤ 3, and no previous systemic chemotherapy, radiotherapy or immune checkpoint inhibitor treatment.\n* Eastern Cooperative Oncology Group performance status of 0 or 1\n* Expected survival time ≥ 3 months\n* Patients must submit a pre-treatment tumor tissue sample during the study.\n* Adequate hematologic and end organ function\n\nExclusion Criteria:\n\n* Spinal cord compression not definitively treated with surgery and\u002For radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for ≥ 1 week prior to randomization\n* Leptomeningeal disease\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures\n* Uncontrolled or symptomatic hypercalcemia\n* Malignancies other than SCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome\n* History of autoimmune disease, including but not limited to myasthenia gravis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease\n* Prior treatment with immune checkpoint blockade therapies\n* Subjects with a condition requiring systemic treatment with either corticosteroids (\\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first administration of study treatment. Inhaled or topical steroids, and adrenal replacement steroid are permitted in the absence of active autoimmune disease.\n* Significant cardiovascular disease\n* Prior allogeneic bone marrow transplantation or solid organ transplant\n* Treatment with systemic immunosuppressive medications within 1 weeks prior to randomization\n* History of hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins, carboplatin or etoposide\n* History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator","75 Years",{"count":273,"type":22},62,[216],"This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of adebelizumab combined with carboplatin\u002FCisplatin plus (+) etoposide and concurrent radiotherapy in the first-line treatment of patients with extensive stage oligometastatic small cell lung cancer.",[156,157,158,159,68,27,277,278,160,279],"Carcinoma, Bronchogenic","Bronchial Neoplasms","Small Cell Lung Carcinoma",[281,282,283,284,285],"Extensive stage small cell lung cancer","Oligometastasis","Adebrelimab","Chemotherapy","Radiotherapy","2023-12-11",{"date":288,"type":42},"2023-12-20",{"date":290,"type":22},"2023-12-10",{"date":292,"type":22},"2026-09-30",{"name":294,"class":84},"Nanfang Hospital, Southern Medical University"]